Inhalation steroids asthma

A 28-week, placebo-controlled US study comparing the safety of salmeterol with placebo, each added to usual asthma therapy, showed an increase in asthma-related deaths in patients receiving salmeterol (13/13,176 in patients treated with salmeterol vs. 3/13,179 in patients treated with placebo; RR , 95% CI , ). The increased risk of asthma-related death is considered a class effect of the longacting beta 2 -adrenergic agonists, including BROVANA Inhalation Solution. No study adequate to determine whether the rate of asthma-related death is increased in patients treated with BROVANA Inhalation Solution has been conducted.

Patients requiring oral corticosteroids should be weaned slowly from systemic corticosteroid use after transferring to ALVESCO. Prednisone reduction can be accomplished by reducing the daily prednisone dose by mg on a weekly basis during ALVESCO therapy [see DOSAGE AND ADMINISTRATION ]. Lung function (FEV 1 or AM PEFR), beta-agonist use, and asthma symptoms should be carefully monitored during withdrawal of oral corticosteroids. In addition to monitoring asthma signs and symptoms, patients should be observed for signs and symptoms of adrenal insufficiency, such as fatigue, lassitude , weakness, nausea and vomiting, and hypotension .

Inhalation steroids asthma

inhalation steroids asthma


inhalation steroids asthmainhalation steroids asthmainhalation steroids asthmainhalation steroids asthmainhalation steroids asthma